|
 The company said on Wednesday its U.S. unit was recalling the
injections as they could potentially deliver an inaccurate dose.
Auvi-Q is designed to treat anaphylaxis, a potentially fatal
allergic reaction, in patients who are at risk or who have a history
of such reactions.
An incorrect dose could lead to significant health issues, Sanofi
said.
The company has received 26 reports of suspected device malfunctions
in the United States and Canada as of Oct. 26.
However, there has been no confirmation on the reports and no deaths
have been reported so far, Sanofi said.
The company's U.S.-listed shares closed at $51.49 on the New York
Stock Exchange on Wednesday.
[to top of second column] |
(Reporting By Samantha Kareen Nair in Bengaluru; Editing by Anil
D'Silva and Kirti Pandey)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
